贵州药代备案管理时间表确定 明年6月底前实施

2017-06-02 田边 赛柏蓝器械

贵州卫计委发布《关于进一步改革完善药品生产流通使用政策实施方案(征求意见稿)》,要求2018年6月底之前,制订并实施《贵州省医药代表登记管理实施办法》。


医药代表备案制度,明年6月底之前开始实施!

医药代表信息网上公布,接受医生、公众监督

6月1日,贵州卫计委发布《关于进一步改革完善药品生产流通使用政策实施方案(征求意见稿)》(下称方案)。

《方案》中,在“加强对医药代表的备案管理”环节表明:将出台贵州省医药代表登记备案管理实施办法,及时完成全省药品生产、经营企业医药代表的登记备案工作,将相关信息上网公布,充分发挥社会监督力量,让医务人员和公众对其合法身份和学术推广行为进行监督。

医药代表不得承担药品销售任务,并实时将其违规销售药品的行为记入个人信用记录。并标注责任单位为:省食药监局和省卫生计生委。

定了,2018年6月底之前实施

值得注意的是,《方案》要求省食药监局和省卫生计生委,在2018年6月底之前,制订《贵州省医药代表登记管理实施办法》并组织实施。

在5月5日国务院办公厅印发的《深化医药卫生体制改革2017年重点工作任务的通知》中,要求食药监总局负责,在2017年12月底前制定医药代表登记备案管理办法。

而在贵州的《方案》中,直接就把制定并实施的时间给确定了,印象里这是第一个,对实施药代备案,给出准确时间表的省份。

药代拥抱阳光,形象将颠覆性扭转

该来的总是要来的。按照国务院的安排,到2017年底,关于药代备案的实施办法就会出台。按照惯例,很可能是总局制定大的框架,各个省份根据具体情况,出台相应的备案管理方法。包括实施细则以及推进的时间表。

不过,制定并实施药代备案,是个行业规范,牵涉面相对较小,相信其实施的进度会非常快。

药代备案的核心要点,在国务院的通知中也提到:就是要公开信息,接受社会监督。在贵州的这个《方案》中,说的就更详细——药企和药商的代表,都要备案,并将其信息上网,接受医生和公众的监督。

让公众了解药代,很大程度上,能够消除一些无谓猜测。公开透明,预示着这个职业将走出灰色地带,拥抱阳光。至少,在世人眼中的形象,将发生颠覆性的扭转。相信,这也是百万药代共同的愿望。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2010982, encodeId=1b48201098264, content=<a href='/topic/show?id=192c424e930' target=_blank style='color:#2F92EE;'>#备案管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42479, encryptionId=192c424e930, topicName=备案管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Jun 15 22:38:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666653, encodeId=89451666653ce, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Apr 03 20:38:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590905, encodeId=53201590905af, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Jun 04 01:38:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205597, encodeId=960720559e93, content=希望这个行业朝着好的方向发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcohE5MKT1FYlH69x7qib45icLgBDMANxIiauEA62nuQI1eE8Ez2rO3yqOkRLH6ha6Lw0x1IBRm0N7g/0, createdBy=e1ff2033933, createdName=187****0626, createdTime=Fri Jun 02 10:45:32 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-06-15 yahu
  2. [GetPortalCommentsPageByObjectIdResponse(id=2010982, encodeId=1b48201098264, content=<a href='/topic/show?id=192c424e930' target=_blank style='color:#2F92EE;'>#备案管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42479, encryptionId=192c424e930, topicName=备案管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Jun 15 22:38:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666653, encodeId=89451666653ce, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Apr 03 20:38:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590905, encodeId=53201590905af, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Jun 04 01:38:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205597, encodeId=960720559e93, content=希望这个行业朝着好的方向发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcohE5MKT1FYlH69x7qib45icLgBDMANxIiauEA62nuQI1eE8Ez2rO3yqOkRLH6ha6Lw0x1IBRm0N7g/0, createdBy=e1ff2033933, createdName=187****0626, createdTime=Fri Jun 02 10:45:32 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2018-04-03 fengyqf
  3. [GetPortalCommentsPageByObjectIdResponse(id=2010982, encodeId=1b48201098264, content=<a href='/topic/show?id=192c424e930' target=_blank style='color:#2F92EE;'>#备案管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42479, encryptionId=192c424e930, topicName=备案管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Jun 15 22:38:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666653, encodeId=89451666653ce, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Apr 03 20:38:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590905, encodeId=53201590905af, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Jun 04 01:38:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205597, encodeId=960720559e93, content=希望这个行业朝着好的方向发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcohE5MKT1FYlH69x7qib45icLgBDMANxIiauEA62nuQI1eE8Ez2rO3yqOkRLH6ha6Lw0x1IBRm0N7g/0, createdBy=e1ff2033933, createdName=187****0626, createdTime=Fri Jun 02 10:45:32 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-06-04 cenghis
  4. [GetPortalCommentsPageByObjectIdResponse(id=2010982, encodeId=1b48201098264, content=<a href='/topic/show?id=192c424e930' target=_blank style='color:#2F92EE;'>#备案管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42479, encryptionId=192c424e930, topicName=备案管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Jun 15 22:38:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666653, encodeId=89451666653ce, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Apr 03 20:38:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590905, encodeId=53201590905af, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Jun 04 01:38:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205597, encodeId=960720559e93, content=希望这个行业朝着好的方向发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcohE5MKT1FYlH69x7qib45icLgBDMANxIiauEA62nuQI1eE8Ez2rO3yqOkRLH6ha6Lw0x1IBRm0N7g/0, createdBy=e1ff2033933, createdName=187****0626, createdTime=Fri Jun 02 10:45:32 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-06-02 187****0626

    希望这个行业朝着好的方向发展

    0